"By the Ministry led the development of the" pharmaceutical industry second Five "(the" Plan ") or will be officially released this month." China Pharmaceutical Enterprise Management Association on July 14, Matilda held in the first five basal thermometer manufacturer Chinese medical and health industry summit, said investment and financing. This "plan" developed with the previous Development and Reform Commission issued a "second Five biomedical development," the Ministry of Commerce issued the "National Development Plan the pharmaceutical distribution industry" (2011 ~ 2015) is the pharmaceutical industry's "Ten automatic digital blood pressure monitor 25 "planning program content.
Matilda said: "The second five" core idea of ??"industrial restructuring, technological upgrading,"upper arm blood pressure monitor manufacturer not the pursuit of speed and number of the current stack, which is the "Eleventh Five-Year Plan" are essentially different. flexible thermometer manufacturer Product standards should be upgraded to be more safe, effective quality assurance system should be improved, which will greatly enhance China'spacifier thermometer manufacturer pharmaceutical industry production levels.
Significant medical value of investments
Matilda predicted that "five" period, China's pharmaceutical industry will produce a series of very positive changes.basal thermometer Original capabilities such as medicine; generic drugs from our country, the original drug to power, to the "five-second" weekend with 25 world-class Chinese people own a class of drugs. In addition, our agents will move toward the European market, there are already 31 European and American companies to obtain certification preparation, "We want to 'second five' to 100. At that time,fever thermometer manufacturer Mr. Obama also eat Chinese medicine would not be a joke. "
wrist blood pressure monitor Many participants in the pharmaceutical industry, investors have shown great enthusiasm, the pharmaceutical industry generally believe that the current valuation is reasonable, long-term value significantly.
Data show: last year China received more than 60 companies a total of 60 billion yuan of investment, equivalent to the sum of 2007 toelectronic thermometer manufacturer 2009. Meanwhile, inside and outside the healthcare industry IPO steadily, becoming the largest number of IPO one of the four industries.
Matilda said at the meeting, to 2015, output value of China's pharmaceutical industry is expected to reach 3.6 trillion to 3.7 trillion yuan level; from the beginning of this year to 2015, average annual growth rate will reach 23% to 24%. 2011 industry profit growth is expected to reach 30%.
Analysts said the stock this year, the core dynamic pharmaceutical industry in the 30 times PE. 30% of the industry profit growth estimates, from the long-term investment perspective, the next 10 years will be China's pharmaceutical industry's gold for 10 years, the industry continued to rely on a stable growth of the pressure to resolve the valuation, pharmaceutical stocks still have a significant long-term investment value.
Clear Research Center data show: first half of 2011, total investment in China's VC market, the case 605, the disclosure of which involved a total amount of 538 from a total investment of $ 6,067,000,000. Biotechnology, health care remains one of the hot investment this year, total investment in the first half of 33 cases, involving an amount of $ 194 million.
It is reported that medical and health industry in developed countries usually accounts for GDP10%, while China, the industry accounts for only less than 4% of GDP. Currently, in China, multinational pharmaceutical companies, large domestic pharmaceutical group of industry consolidation, mergers and acquisitions are increasingly active in national policy to encourage private capital to enter the medical field. Therefore, a large number of medical and health industry is becoming the focus of the newly established PE fund to invest.
Matilda analysis of the visited companies found that for many businesses, capital, technology is important, but the impact of the development of enterprises, especially pharmaceutical companies is the most central policy environment. Matilda calls on the Government should establish a stable policy environment.
At the meeting, told reporters some of the investment and financing, due to policy uncertainty, institutional long-term bullish for a number of areas such as medical, short-term on the sidelines.